Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
51.09
+0.51 (+1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
From
Genentech
Via
Business Wire
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
April 24, 2026
From
Genentech
Via
Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
April 22, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
April 22, 2026
From
BioMedWire
Via
GlobeNewswire
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
April 21, 2026
From
Genentech
Via
Business Wire
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 21, 2026
From
Genentech
Via
Business Wire
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
From
Genentech
Via
Business Wire
Could AbbVie Crash Lilly's Weight‑Loss Party?
↗
April 14, 2026
AbbVie is making progress in this market, but it is still far behind the leader.
Via
The Motley Fool
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
April 13, 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 09, 2026
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
April 06, 2026
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis...
Via
MarketMinute
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...
Via
MarketMinute
Topics
Economy
World Trade
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
April 03, 2026
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...
Via
MarketMinute
Topics
Intellectual Property
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
April 03, 2026
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...
Via
MarketMinute
Topics
Economy
Government
Lawsuit
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
April 03, 2026
By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...
Via
Finterra
Topics
Economy
Intellectual Property
World Trade
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
April 02, 2026
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...
Via
MarketMinute
Topics
Intellectual Property
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
April 02, 2026
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive...
Via
MarketMinute
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
March 31, 2026
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...
Via
MarketMinute
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
March 31, 2026
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY)....
Via
Finterra
Topics
Economy
Intellectual Property
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
March 27, 2026
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...
Via
MarketMinute
Topics
Intellectual Property
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
March 26, 2026
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study....
Via
MarketMinute
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....
Via
MarketMinute
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
March 25, 2026
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF
↗
March 24, 2026
The Vanguard International High Dividend Yield ETF holds more than 1,500 stocks and yields 3.3%.
Via
The Motley Fool
Topics
ETFs
Retirement
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
March 23, 2026
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)...
Via
MarketMinute
Topics
Supply Chain
The Best Healthcare Stocks to Buy With $50 Right Now
↗
March 18, 2026
Even on a budget, you can get quality stocks.
Via
The Motley Fool
Is Eli Lilly's Weight Loss Empire in Trouble?
↗
March 13, 2026
It won't be easy to knock the company off its pedestal.
Via
The Motley Fool
3 ETFs to Avoid as Oil Shock Hits Markets
↗
March 12, 2026
Via
MarketBeat
Topics
ETFs
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
March 09, 2026
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
